A Pharmacoeconomic Model for the Treatment of Influenza
- 27 Downloads
Objective: The aim of this study was to develop a generic treatment algorithm for influenza and influenza-like illness (ILI) that could be used to estimate the costs and outcomes of current and new treatments for influenza in different countries for different patient subgroups.
Methods: A series of possible treatment pathways was identified and the probabilities of different patient subgroups following each pathway were estimated by using the published literature. The health outcomes and health service use and unit costs for each pathway were estimated from trial data and standard data sources. An interactive computer model was created, the base-case input parameter values were assigned, and estimates of the current costs of influenza and ILI in different population subgroups estimated. Sensitivity analyses were performed by changing input parameter values.
Results: The average healthcare cost of influenza and ILI per person in the US was $US72 for the general population and $US330 for a high risk population (1997 values). The average total cost per patient (healthcare cost plus productivity losses) was $US320 for the general population and $US546 for a high risk population. These costs are sensitive to changes in the proportion of patients visiting a physician and to the proportion of patients hospitalised with complications of the disease. Days to alleviate major symptoms and other health outcome measures are sensitive to the percentage of patients who receive antiviral therapy as well as to the efficacy of this therapy.
Conclusions: The costs and health outcomes of influenza and ILI depend on the extent to which patients visit a physician, the use of antiviral drugs, and the incidence of complications requiring hospital care. The computer model will allow decision-makers to assess the cost effectiveness and the potential budget impact of new antivirals for treating influenza.
Unable to display preview. Download preview PDF.
- 3.Schoenbaum SC. Economic impact of influenza. Am J Med 1987; 295: 759–65Google Scholar
- 5.Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR 1998; 47 Suppl. (RR-6): 1–26Google Scholar
- 7.Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24–27; San Diego, 1998Google Scholar
- 9.Department of Health and Human Services. National Ambulatory Medical Care Survey. Washington DC: Department of Health and Human Services, 1990Google Scholar
- 10.Department of Health and Human Services. National Hospital Discharge Survey. Washington DC: Department of Health and Human Services, 1990Google Scholar
- 13.Silagy CA, Griffin AD, Lacey LA, et al. Impact of zanamivir on health status, productivity and healthcare resource use in patients with influenza. Annual Meeting of the Infectious Disease Society of America; 1998 Nov 12–15: Denver, COGoogle Scholar
- 14.Red Book. 1995Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc., 1995Google Scholar
- 15.US Bureau of the Census. Statistical abstract of the United States: 1994, 114th ed. Washington, DC: US Bureau of the Census, 1994Google Scholar
- 18.US Congress, Office of Technology Assessment (OTA). Cost effectiveness of influenza vaccination. Washington, DC: US Government Printing Office, 1981. Publication No: OTA-H-152Google Scholar